Peter Hoang Joins Kiromic BioPharma, Inc. Board of Directors
Houston, Texas, Oct.16, 2017 – Kiromic Inc., today announced the appointment of Peter Hoang to its Board of Directors. Mr. Hoang is Chief Executive Officer of TapImmune, a clinical-stage immuno-oncology company.
About Kiromic Biopharma
Kiromic is a clinical-stage immuno-oncology biopharmaceutical company with a breakthrough artificial intelligence called KAI, and drug discovery programs across multiple technology platforms; including cellular therapies, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.